The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies

Paul S. Frenette, Michael P. Thirlwell, Marc Trudeau, D. M P Thomson, Lawrence Joseph, Joseph S. Shuster

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

In the past decade, considerable interest has arisen for defining the role of various tumor markers in the diagnosis of cancer. This cross-sectional study evaluates four breast cancer markers (CA 27-29, CA 15-3, MCA and CEA) and two gastrointestinal (GI) markers (CA 19-9 and CEA) in 213 patients. Receiver operating curves (ROC) revealed a sensitivity for the 90% specificity cutoff for breast cancers compared to breast benign diseases of 70% for CA 27-29, 67.5% for CA 15-3, 52.5% for MCA and 40% for CEA. When GI tumors were compared to benign GI disease, the sensitivity for 90% specificity was 40.3% for CEA and 32.3% for CA 19-9. Comparison of breast cancer and GI malignancies with other malignancies leads to a marked shift of the ROC curve to the right and loss of specificity. Late stage for all breast and GI tumor markers was found to be a predictor of high serum antigen level (p < 0.001). The presence of liver metastases in breast cancer was associated with abnormal levels of CA 27-29 (p = 0.028). Pancreas adenocarcinomas had a higher CA 19-9 antigen level (p < 0.001) than other GI malignancies. CA 27-29 appears to be at least as sensitive and specific as CA 15-3 in patients with breast cancer. None of the above markers retain their specificity when compared with a control group consisting of other malignancies.

Original languageEnglish (US)
Pages (from-to)247-254
Number of pages8
JournalTumor Biology
Volume15
Issue number5
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Mucin-3
Tumor-Associated Carbohydrate Antigens
Carcinoembryonic Antigen
Breast
Breast Neoplasms
Carcinoma
Neoplasms
Tumor Biomarkers
CA-19-9 Antigen
Sensitivity and Specificity
Breast Diseases
Gastrointestinal Diseases
Pancreas
Adenocarcinoma
Cross-Sectional Studies
Neoplasm Metastasis
Antigens
Control Groups
Liver

Keywords

  • Breast cancer
  • CA 15-3
  • CA 19-9
  • CA 27-19
  • Carcinoembryonic antigen
  • Colon cancer
  • Mucin-like carcinoma antigen
  • Pancreas cancer
  • Tumor antigen
  • Tumor markers

ASJC Scopus subject areas

  • Cancer Research

Cite this

The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies. / Frenette, Paul S.; Thirlwell, Michael P.; Trudeau, Marc; Thomson, D. M P; Joseph, Lawrence; Shuster, Joseph S.

In: Tumor Biology, Vol. 15, No. 5, 1994, p. 247-254.

Research output: Contribution to journalArticle

Frenette, Paul S. ; Thirlwell, Michael P. ; Trudeau, Marc ; Thomson, D. M P ; Joseph, Lawrence ; Shuster, Joseph S. / The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies. In: Tumor Biology. 1994 ; Vol. 15, No. 5. pp. 247-254.
@article{005415315224419aa183e8e5e999180b,
title = "The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies",
abstract = "In the past decade, considerable interest has arisen for defining the role of various tumor markers in the diagnosis of cancer. This cross-sectional study evaluates four breast cancer markers (CA 27-29, CA 15-3, MCA and CEA) and two gastrointestinal (GI) markers (CA 19-9 and CEA) in 213 patients. Receiver operating curves (ROC) revealed a sensitivity for the 90{\%} specificity cutoff for breast cancers compared to breast benign diseases of 70{\%} for CA 27-29, 67.5{\%} for CA 15-3, 52.5{\%} for MCA and 40{\%} for CEA. When GI tumors were compared to benign GI disease, the sensitivity for 90{\%} specificity was 40.3{\%} for CEA and 32.3{\%} for CA 19-9. Comparison of breast cancer and GI malignancies with other malignancies leads to a marked shift of the ROC curve to the right and loss of specificity. Late stage for all breast and GI tumor markers was found to be a predictor of high serum antigen level (p < 0.001). The presence of liver metastases in breast cancer was associated with abnormal levels of CA 27-29 (p = 0.028). Pancreas adenocarcinomas had a higher CA 19-9 antigen level (p < 0.001) than other GI malignancies. CA 27-29 appears to be at least as sensitive and specific as CA 15-3 in patients with breast cancer. None of the above markers retain their specificity when compared with a control group consisting of other malignancies.",
keywords = "Breast cancer, CA 15-3, CA 19-9, CA 27-19, Carcinoembryonic antigen, Colon cancer, Mucin-like carcinoma antigen, Pancreas cancer, Tumor antigen, Tumor markers",
author = "Frenette, {Paul S.} and Thirlwell, {Michael P.} and Marc Trudeau and Thomson, {D. M P} and Lawrence Joseph and Shuster, {Joseph S.}",
year = "1994",
doi = "10.1159/000217898",
language = "English (US)",
volume = "15",
pages = "247--254",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "5",

}

TY - JOUR

T1 - The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies

AU - Frenette, Paul S.

AU - Thirlwell, Michael P.

AU - Trudeau, Marc

AU - Thomson, D. M P

AU - Joseph, Lawrence

AU - Shuster, Joseph S.

PY - 1994

Y1 - 1994

N2 - In the past decade, considerable interest has arisen for defining the role of various tumor markers in the diagnosis of cancer. This cross-sectional study evaluates four breast cancer markers (CA 27-29, CA 15-3, MCA and CEA) and two gastrointestinal (GI) markers (CA 19-9 and CEA) in 213 patients. Receiver operating curves (ROC) revealed a sensitivity for the 90% specificity cutoff for breast cancers compared to breast benign diseases of 70% for CA 27-29, 67.5% for CA 15-3, 52.5% for MCA and 40% for CEA. When GI tumors were compared to benign GI disease, the sensitivity for 90% specificity was 40.3% for CEA and 32.3% for CA 19-9. Comparison of breast cancer and GI malignancies with other malignancies leads to a marked shift of the ROC curve to the right and loss of specificity. Late stage for all breast and GI tumor markers was found to be a predictor of high serum antigen level (p < 0.001). The presence of liver metastases in breast cancer was associated with abnormal levels of CA 27-29 (p = 0.028). Pancreas adenocarcinomas had a higher CA 19-9 antigen level (p < 0.001) than other GI malignancies. CA 27-29 appears to be at least as sensitive and specific as CA 15-3 in patients with breast cancer. None of the above markers retain their specificity when compared with a control group consisting of other malignancies.

AB - In the past decade, considerable interest has arisen for defining the role of various tumor markers in the diagnosis of cancer. This cross-sectional study evaluates four breast cancer markers (CA 27-29, CA 15-3, MCA and CEA) and two gastrointestinal (GI) markers (CA 19-9 and CEA) in 213 patients. Receiver operating curves (ROC) revealed a sensitivity for the 90% specificity cutoff for breast cancers compared to breast benign diseases of 70% for CA 27-29, 67.5% for CA 15-3, 52.5% for MCA and 40% for CEA. When GI tumors were compared to benign GI disease, the sensitivity for 90% specificity was 40.3% for CEA and 32.3% for CA 19-9. Comparison of breast cancer and GI malignancies with other malignancies leads to a marked shift of the ROC curve to the right and loss of specificity. Late stage for all breast and GI tumor markers was found to be a predictor of high serum antigen level (p < 0.001). The presence of liver metastases in breast cancer was associated with abnormal levels of CA 27-29 (p = 0.028). Pancreas adenocarcinomas had a higher CA 19-9 antigen level (p < 0.001) than other GI malignancies. CA 27-29 appears to be at least as sensitive and specific as CA 15-3 in patients with breast cancer. None of the above markers retain their specificity when compared with a control group consisting of other malignancies.

KW - Breast cancer

KW - CA 15-3

KW - CA 19-9

KW - CA 27-19

KW - Carcinoembryonic antigen

KW - Colon cancer

KW - Mucin-like carcinoma antigen

KW - Pancreas cancer

KW - Tumor antigen

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=0028153269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028153269&partnerID=8YFLogxK

U2 - 10.1159/000217898

DO - 10.1159/000217898

M3 - Article

C2 - 7991985

AN - SCOPUS:0028153269

VL - 15

SP - 247

EP - 254

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 5

ER -